The Translational Breast Cancer Research Consortium (TBCRC) is designing the TRADE-DXd trial, which will enroll patients with HER2-low metastatic breast cancer (mBC), with 0–1 prior lines of therapy and no previous topo-1 inhibitors. This evidence concerns the gene ERBB2 and breast cancer.